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The T helper 17 (Th17) cell lineage is important in in-
flammatory and autoimmune responses, via its abil-
ity to produce interleukin-17 (IL-17) and IL-21. Given
the potentially deleterious effects of Th17 cells, their
generation needs to be strictly controlled. IRF-4 is
a transcription factor that has recently emerged as
a key regulator of Th17 cell differentiation. Here, we
showed that mice deficient in a previously isolated
protein, IBP (IRF-4-binding protein), rapidly devel-
oped rheumatoid arthritis-like joint disease and
large-vessel vasculitis. The pathology was associ-
ated with an enhanced responsiveness of T cells to
low levels of stimulation and with the inappropriate
synthesis of IL-17 and IL-21. IBP sequestered IRF-4
and prevented it from targeting the transcriptional
regulatory regions of the genes that encode IL-17
and IL-21. Thus, IBP appears to be important in pre-
venting T cell-mediated autoimmunity by ensuring
that the production of IL-17 and IL-21 does not occur
in response to self-antigens.
INTRODUCTION
Recent studies have uncovered the existence of a T helper cell
effector subset, the Th17 cell lineage, whose deregulation has
been implicated in the pathogenesis of autoimmunity (Bettelli
et al., 2007b;Weaver et al., 2006). In particular, Th17 cells are be-
lieved to play a key role in rheumatoid arthritis (RA) (McInnes and
Schett, 2007; Toh and Miossec, 2007), a disease characterized
by destructive inflammatory lesions affecting the synovial mem-
branes of joints and by aberrant humoral responses that result
in the production of autoantibodies such as rheumatoid factor
and cyclic citrullinated peptide (CCP) antibodies. The ability of
the Th17 cell subset to produce IL-17 is critical to their role in
RA pathogenesis because IL-17 can induce the production of
proinflammatory cytokines such as TNF-a and IL-1 as well as
stimulate matrix metalloproteinase activity, matrix catabolism,
and bone resorption (Koenders et al., 2006; Stamp et al., 2004).
Th17 cells have also recently been shown to produce IL-21(Korn et al., 2007; Nurieva et al., 2007; Zhou et al., 2007), a cyto-
kine that can amplify the differentiation of Th17 cells in an
autocrine manner as well as control T-dependent humoral
responses (Leonard and Spolski, 2005; Mehta et al., 2004).
Th17 cells develop via a pathway distinct from Th1 and Th2 cells.
Induction of IL-17 production depends on the presence of the
transcription factors STAT3 and RORgt (Ivanov et al., 2006; Lau-
rence et al., 2007; Yang et al., 2007), whereas IL-21 expression
requires the presence of STAT3 but not of RORgt (Nurieva
et al., 2007). Given the potentially deleterious effects of the
cytokines produced by Th17 cells, their production needs to be
strictly controlled so that acquisition of these effector functions
occurs only in response to the appropriate antigenic stimuli.
The regulatory pathways that prevent the inappropriate produc-
tion of IL-17 and IL-21 have, however, not been fully elucidated.
Interferon regulatory factor 4 (IRF-4) is a member of the IRF
family of transcription factors whose absence leads to profound
defects in the function and homeostasis of mature T and B cells
(Mittru¨cker et al., 1997). Expression of IRF-4 is upregulated in
response to T cell activation and we, as well as others, have
shown that IRF-4 can regulate IL-4 production and Th2 cell differ-
entiation (Hu et al., 2002; Rengarajan et al., 2002). Interestingly,
recent studies have demonstrated that IRF-4 is also a crucial
regulator of Th17 cell differentiation (Brustle et al., 2007). During
a yeast two-hybrid screen aimed at identifying proteins interact-
ing with IRF-4, our laboratory isolated a human cDNA encoding
a protein that we termed IBP (IRF-4-binding protein) (Gupta
et al., 2003b). IBP (encoded by the geneDef6) shares substantial
homology with SWAP-70, a Rac activator. In contrast to SWAP-
70 that is expressedmostly in B cells andmast cells, IBP is highly
expressed in T cells. In unstimulated T cells, IBP is present in a
‘‘dormant’’ conformation due to an inhibitory interaction between
its N- and C-termini. T cell receptor (TCR) engagement leads to
the tyrosine phosphorylation of the N-terminus of IBP, disrupting
the autoinhibitory interaction and enabling IBP to be recruited
to the immunological synapse (IS) where IBP activates Rac and
Cdc42 (Gupta et al., 2003a). Our previous studies in mice defi-
cient for IBP (Def6trap/trap mice) have revealed that lack of IBP,
with age, leads to the development of a lupus-like syndrome,
which is characterized by the accumulation of CD44hiCD62Llo
T cells and IgG+ B cells, profound hypergammaglobulinemia,
autoantibody production, proteinuria, and glomerulonephritis
(Fanzo et al., 2006). Consistent with the ability of IBP to act asImmunity 29, 899–911, December 19, 2008 ª2008 Elsevier Inc. 899
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IBP Inhibits IL-17 and IL-21 Production by Regulating IRF-4an activator of Rho GTPases, IBP-deficient T cells exhibited
defects in ERK1 and ERK2 activation and in cytoskeletal
reorganization including impaired assembly of the IS and actin
polymerization.
We have generated TCR transgenic (DO11.10) IBP-deficient
mice. Surprisingly, these mice rapidly developed, with a high
degree of penetrance, an autoimmune condition marked by the
presence of rheumatoid arthritis-like joint disease and large-
vessel vasculitis. In contrast to the SKGmouse, in which sponta-
neous development of arthritis is linked to the emergence of
autoreactive T cell clones secondary to impairments in negative
selection (Sakaguchi et al., 2003), thymocyte negative selection
was not affected by the lack of IBP. The pathology observed in
the absence of IBPwas instead associated with an accumulation
of TCR transgene positive T cells, which exhibited an altered
pattern of responsiveness to pMHC complexes and aberrantly
expressed both IL-17 and IL-21. Importantly, our studies demon-
strated that the aberrant cytokine production observed in the
absence of IBP was due to the lack of IRF-4 regulation. Thus,
the absence of IBP leads to autoimmunity because of the ability
of IBP to control both the TCR signaling threshold as well as the
acquisition of pathogenic Th cell effector functions.
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Figure 1. Development of Arthritis and
Large-Vessel Vasculitis in Def6trap/trap
DO11.10 Mice
(A) Histopathologic analysis (hematoxylin-eosin
staining) of wrist joints of a 12-week-old female
Def6+/+ DO11.10 mouse (left) and an age- and
sex- matched Def6trap/trap DO11.10 mouse (right).
Light-microscopy images (magnification of 403
and 1003, as indicated) are shown. These find-
ings are representative of six mice for each group.
(B) Serological analysis. Sera from Def6+/+
DO11.10 and Def6trap/trap DO11.10 mice (6–25
weeks old, male and female, n = 6–12) were
collected and amounts of rheumatoid factor
(RF), collagen II (CII) antibodies, and cyclic citrulli-
nated peptide (CCP) antibodies were analyzed by
ELISA. Horizontal lines denote mean values. *p <
0.05.
(C) Histopathologic analysis (hematoxylin-eosin
staining) of the root of the aorta of a 16-week-
old Def6+/+ DO11.10 female mouse (left panels)
and an age-matched Def6trap/trap DO11.10 female
mouse (right panels). Light-microscopy images
(magnification of 403 and 1003, as indicated)
are shown. These findings are representative of
six mice for each group.
RESULTS
Spontaneous Development of
Rheumatoid Arthritis-like Joint
Disease and Large-Vessel
Vasculitis in Def6trap/trap
DO11.10 Mice
To systematically analyze the effects
of IBP deficiency on TCR-mediated
signaling pathways, we backcrossed
Def6trap/trap mice onto a BALB/c back-
ground and then crossed them to DO11.10 mice, which carry
a I-Ad-restricted transgenic T cell receptor that recognizes a spe-
cific peptide (OVA323-339) derived from ovalbumin (Murphy et al.,
1990;Robertsonet al., 2000).Surprisingly, beginningat7weeks
of age, Def6trap/trap DO11.10 mice but none of the Def6+/+
DO11.10 mice started spontaneously developing joint erythema
and swelling, which affected the wrist joints and fingers and,
less frequently, the ankle joints and toes in a symmetricalmanner.
No obvious swelling of the knees, elbows, shoulders, or vertebral
jointswas observed. Approximately 90%ofDef6trap/trap DO11.10
mice developed a chronic progressive arthritis, which tended to
be more severe in females and occasionally resulted in joint de-
formities and impairedmobility (FigureS1available online). Histo-
pathologic analysis revealed synovitis with pannus formation,
composed predominantly of fibroblasts, monocytes, lympho-
cytes, anda variable number of plasmacells andneutrophils (Fig-
ure 1A and data not shown). The infiltrate invaded the adjacent
joint structure with destruction of cartilage and increased osteo-
clastic activity leading to resorption of the subchondral bone and
bone erosions. Serologic analysis demonstrated thatDef6trap/trap
DO11.10mice exhibited elevated titers of rheumatoid factor (RF),
collagen II antibodies, and cyclic citrullinated peptide antibodies900 Immunity 29, 899–911, December 19, 2008 ª2008 Elsevier Inc.
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IBP Inhibits IL-17 and IL-21 Production by Regulating IRF-4(CCPs) in their serum but only a small increase in dsDNA
antibodies (Figure 1B and Figure S1). Def6trap/trap DO11.10
mice thus develop an inflammatory arthropathy that shares
many clinical, histological, and serological features with human
rheumatoid arthritis.
Beginning at3months of age,Def6trap/trap DO11.10mice also
started dying suddenly. More than 90% of Def6trap/trap DO11.10
mice had died by 12 months of age with female Def6trap/trap
DO11.10 mice dying more rapidly than male Def6trap/trap
DO11.10 mice (Figure S1). Consistent with the idea that the
sudden death of the Def6trap/trap DO11.10 mice might be due to
abnormalities of their cardiovascular system, histologic analysis
revealed that all of the arthritic Def6trap/trap DO11.10 mice also
had developed severe inflammation of the root of the aorta with
massive transmural infiltration of lymphocytes and monocytes,
includingoccasionalmultinucleatedgiant cells, variable numbers
of plasma cells and neutrophils, and reduplication or destruction
of the internal elastic lamina (Figure 1Cand Figure S1). Occasion-
ally, inflammation was also observed in the medium-sized
arteries of the kidney and of the lung, but not veins or capillaries.
No significant inflammation of other organs was noted, including
the small and large intestine, pancreas, and liver.
IBP Deficiency Leads to Abnormal TCR Responsiveness
To explore the pathways underlying the pathology associated
with IBP deficiency, we first investigated whether lack of IBP
leads to abnormalities in central tolerance. Unlike what has been
described for previousmurinemodels, the emergence of sponta-
neous arthritis and vasculitis in the Def6trap/trap DO11.10 mice
was not due to a failure of eliminating autoreactive T cells within
the thymus, as assessed by injecting Def6+/+ and Def6trap/trap
mice with high doses of anti-CD3 (Figure S2) or by crossing
Def6trap/trap mice with HY transgenic mice, a well-characterized
model of negative selection (Figure S2). Furthermore, no defects
in the development or function of regulatory T cells could be
observed in the absence of IBP (Figures S3 and S4).
These findings raised the possibility that the immunopathology
observed in theDef6trap/trap DO11.10 micemight bemediated by
mature CD4+ T cells secondary to an enhanced recognition of
self-peptides by the Def6trap/trap DO11.10 TCR in the periphery.
Consistent with this idea, expression of CD5, a gauge of the
strength of TCR signaling upon interaction with self-ligands
(Kieper et al., 2004), was greater on Def6trap/trap DO11.10 CD4+
T cells than on Def6+/+ DO11.10 CD4+ T cells. Increased CD5
expression was observed in peripheral CD4+ T cells from adult
mice as well as in thymic CD4SP cells from newborn Def6trap/trap
DO11.10 mice (Figure S5). To directly evaluate whether IBP
deficiency leads to abnormalities in the recognition of pMHC
complexesby theDO11.10TCR,weassayed the responsiveness
of purified naive Def6trap/trap DO11.10 CD4+ T cells to different
doses of OVA323-339 peptide in vitro (Figure 2A). As expected,
the proliferative responses of the Def6+/+ DO11.10 CD4+ T cells
increased upon exposure to increasing doses of OVA323-339
peptide. In contrast,Def6trap/trap DO11.10 CD4+ T cells displayed
a markedly abnormal pattern of proliferation, which was charac-
terized by hyperresponsiveness to low doses of OVA323-339
peptide but hyporesponsiveness to high doses of the same
peptide. Thus, in the absence of IBP, mature CD4+ T cells
become hyperresponsive to low levels of stimulation.The abnormal responsiveness exhibited by the Def6trap/trap
DO11.10 T cells to pMHC complexes suggested that, in the
absence of IBP, TCR transgenic T cells might become spontane-
ously activated in response to endogenous peptides. Indeed, by
6 weeks of age (before the onset of the autoimmune phenotype),
30% of CD4+ T cells from Def6trap/trap DO11.10 mice exhibited
an effector phenotype (Figure 2B). Staining with KJ1-26, a clono-
typic monoclonal antibody that recognizes the DO11.10 TCR,
demonstrated that most of the CD62LloCD44hi T cells were
KJ1-26hi and thus expressed the TCR transgene (Figure S6).
Furthermore, by 6 weeks of age, and even more markedly by
15 weeks of age, KJ1-26hi Def6trap/trap CD4+ T cells spontane-
ously upregulated the expression of CD69 and of inducible
T cell costimulator (ICOS) (Figure 2C). Although an increase in
KJ1-26lo T cells was also observed in the Def6trap/trap DO11.10
mice, these KJ1-26lo T cells expressed a naive phenotype
(Figure S6).
To investigate whether transfer of the Def6trap/trap DO11.10
T cells could mediate pathogenic effector functions, we trans-
ferred total splenocytes from the arthritic Def6trap/trap DO11.10
mice into syngeneic SCID mice. These transfers were accompa-
nied by the sudden demise of 6 out of 14 recipient mice by
3 months, whereas no deaths were recorded in mice receiving
Def6+/+ DO11.10 splenocytes (0/9 recipient mice). No premoni-
tory signs of morbidity were evident in the recipients of
Def6trap/trap DO11.10 lymphocytes that suddenly died, leading
us to suspect that these mice succumbed to the profound
cardiovascular abnormalities associated with the absence of
IBP. Transfer of serum from arthritic Def6trap/trap DO11.10 mice
instead did not lead to any pathology (data not shown). Consis-
tent with the finding that the abnormal acquisition of effector
markers and costimulatory molecules mapped to the KJ1-26hi
rather than to the KJ1-26lo T cell compartment, transfer of puri-
fied KJ1-26hi Def6trap/trap DO11.10 T cells but not of purified
KJ1-26lo Def6trap/trap DO11.10 T cells into nude Balb/c mice
also led to the sudden death of the recipient mice (Figure 2D).
Thus, these data suggest that the pathogenic effects observed
in the absence of IBP were mediated by T cells bearing the
transgenic TCR.
IBP Deficiency Leads to the Aberrant Production
of IL-17 and IL-21
The distinctive pathophysiology observed in the absence of IBP
indicated that IBP, besides regulating TCR responsiveness,
could also control T cell-effector function. In particular, the pres-
ence of both inflammatory lesions and aberrant humoral re-
sponses in the Def6trap/trap DO11.10 mice raised the possibility
that IBP could regulate the production of IL-17 and IL-21. To in-
vestigate this hypothesis, we assessed cytokine production after
obtaining naiveCD4+T cells from5-week-oldDef6+/+DO11.10 or
Def6trap/trap DO11.10 mice by negative depletion (Lin et al., 2004)
and culturing them with antigen presenting cells (APCs) pulsed
with OVA323-339 peptide. When compared to Def6
+/+ T cells,
Def6trap/trap DO11.10 T cells exhibited an increased ability to
produce IL-17 (Figure 3A). Furthermore, in contrast to Def6+/+
DO11.10 T cells, Def6trap/trap DO11.10 T cells also synthesized
substantial amounts of IL-21 (Figure 3A). Deregulated production
of IL-17 and IL-21 was not due to global upregulation in cytokine
production becauseDef6trap/trap DO11.10CD4+ T cells producedImmunity 29, 899–911, December 19, 2008 ª2008 Elsevier Inc. 901
Immunity
IBP Inhibits IL-17 and IL-21 Production by Regulating IRF-4less IL-2 thanDef6+/+ DO11.10 CD4+ T cells (Figure 3A) and vari-
able amounts of IL-4 and IFN-g (Figure S7). A similar increase in
IL-17 and IL-21 production was also detected with FACS-sorted
CD44loCD62LhiCD25-CD4+ Def6trap/trap DO11.10 cells (Fig-
ure S8). The deregulated production of IL-17 and IL-21 observed
upon stimulation ofDef6trap/trap DO11.10 CD4+ T cells under neu-
tral conditions was accompanied by increased expression of
RORgt but not by elevation of IL-22 (Figure 3B).
To assesswhether the aberrant synthesis of IL-17 and IL-21 by
Def6trap/trap DO11.10 cells detected in vitro led to deregulated
production of IL-17 and IL-21 in vivo as well, we evaluated
the concentrations of IL-17 and IL-21 in the sera of arthritic
Def6trap/trap DO11.10 mice (Figure 3C). As compared to Def6+/+
DO11.10 mice, Def6trap/trap DO11.10 mice exhibited increased
serum concentrations of both IL-17 and IL-21. Increased expres-
sion of IL-17 and IL-21 was also observed in the joints of the
arthritic Def6trap/trap DO11.10 mice (Figure 3D). Furthermore,
consistent with the fact that aberrant production of IL-21 by
IBP-deficient CD4+ T cells might enable these T cells to inappro-
priately drive the terminal differentiation of B cells, immunohisto-
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Figure 2. Lack of IBP Leads to Abnormali-
ties in the Responsiveness of DO11.10
CD4+ T Cells
(A) Proliferative responses to OVA323-339 peptide.
Naive CD4+ T cells (CD44loCD62Lhi) were isolated
from both Def6+/+ DO11.10 (blue) and Def6trap/trap
DO11.10 (red) mice and stimulated for 3 days
with Def6+/+ APCs pulsed with increasing doses
(0, 0.1, 1, 10 mM) of OVA323-339 peptide. Cell pro-
liferation was assayed by BrdU ELISA. Data
show mean ± SD and are representative of three
independent experiments.
(B) Spontaneous acquisition of an effector pheno-
type in vivo in the absence of IBP. FACS analysis
of CD44 and CD62L expression on CD4+ splenic
T cells from a 6-week-old female Def6+/+
DO11.10 (left) and a sex- and age- matched
Def6trap/trap DO11.10 (right) mouse. Numbers in
each quadrant represent the percentage of
CD4+ T cells.
(C) Spontaneous activation of Def6trap/trap
DO11.10 T cells in vivo. The surface-expression
level of CD69, CD25, and ICOS on KJ1-26hi
Def6+/+ DO11.10 (blue) and KJ1-26hi Def6trap/trap
DO11.10 (red) T cells was analyzed by FACS
and overlaid histograms are shown. Data are
representative of three mice/group.
(D) Adoptive transfers. Splenocytes, purified
CD4+ T cells, or sorted KJ1-26hi or KJ1-26lo
T cells from Def6+/+ DO11.10 or Def6trap/trap
DO11.10 mice were transferred into syngeneic
SCID or nude mice as indicated. Numbers in
parentheses show the number of recipient mice
that suddenly died over the total number of recip-
ients in each group.
chemical staining of spleen sections
revealed that, in the absence of IBP, nu-
merous plasma cells could be observed
within the T cell zones or perivascular
lymphoid sheaths (Figure 3E). Taken to-
gether, these data indicate that lack of IBP leads to the inappro-
priate synthesis of IL-17 and IL-21, whose production should be
tightly controlled and occur only upon exposure to selected
pathogens.
IRF-4 Controls Both IL-17 and IL-21 Production
The deregulated production of IL-17 and IL-21 by Def6trap/trap
DO11.10 CD4+ T cells could be detected even under conditions
in which these cells displayed proliferative responses identical to
those exhibited by the Def6+/+ DO11.10 CD4+ T cells (i.e., with
1 mMOVA323-339 peptide), suggesting that the abnormal cytokine
production was not simply the result of the aberrant TCR respon-
siveness displayed by these cells. Given that we had originally
cloned IBP as a protein interacting with the transcription factor
IRF-4 (Gupta et al., 2003b), we hypothesized that these effects
might be linked to the ability of IBP to modulate IRF-4 function.
To start exploring this possibility, we first investigated whether
IRF-4 could regulate not only the synthesis of IL-17 but also
that of IL-21. For these studies, we took advantage of previously
generated IRF-4 deficient mice (Mittru¨cker et al., 1997). Naive902 Immunity 29, 899–911, December 19, 2008 ª2008 Elsevier Inc.
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IBP Inhibits IL-17 and IL-21 Production by Regulating IRF-4CD4+ T cells were purified from wild-type (Irf4+/+) and Irf4/
mice and cultured in vitro under Th0 and Th17 cell conditions.
Consistent with recent observations (Brustle et al., 2007), Irf4+/+
CD4+ T cells produced substantial amounts of IL-17 when
cultured under Th17 cell conditions, but CD4+ T cells derived
from Irf4/ mice completely lost their ability to synthesize
IL-17 (Figure 4A). These results were further confirmed by per-
forming intracellular FACS (Figure 4B). In contrast to Irf4+/+
T cells, no IL-17-producing cells could be detected upon stimu-
lation in the absence of IRF-4. The lack of IRF-4 instead resulted
in an enhanced ability to produce IFN-g under Th17 cell condi-
tions. Importantly, when the production of IL-21 was investi-
gated, no IL-21 synthesis could be observed when IRF-4-defi-
cient T cells were cultured under Th17 cell conditions and then
restimulated (Figure 4C). Because the absence of IL-21 produc-
tion in this setting could be secondary to the defective synthesis
of IL-17, and because IL-21 can also be produced by Th2 cells
(Leonard and Spolski, 2005; Mehta et al., 2004), we also investi-
gated the effects of IRF-4 deficiency on IL-21 synthesis when
CD4+ T cells were differentiated under Th2 cell conditions. As
shown in Figure 4D, production of IL-21 under these culture
conditions was also abrogated by the absence of IRF-4.
A survey of the IL-21 promoter revealed that it contains poten-
tial IRF-4-binding elements, we thus proceeded to directly test
whether IRF-4 could function as a transactivator of the IL-21 pro-
moter. To this end, we performed transient-transfection assays
in Jurkat cells that either lacked or contained IRF-4 (Hu et al.,
2002). Consistent with studies demonstrating that NFAT proteins
participate in the regulation of the IL-21 promoter (Kim et al.,
2005; Mehta et al., 2005), inducibility of a luciferase reporter
construct driven by the IL-21 promoter could be observed in
Jurkat cells lacking IRF-4 upon stimulation with PMA and iono-
mycin (Figure 4E). Importantly however, under these stimulatory
conditions, Jurkat cells expressing IRF-4 demonstrated greater
luciferase activity when transfected with the IL-21 promoter
construct (IL-21 LUC) but not with an IL-21 promoter construct
containing mutations within the IRF-4 binding site (IL-21 MUT
LUC). These findings thus indicate that IRF-4 can act as a trans-
activator of the IL-21 promoter and suggest that NFAT proteins
and IRF-4 cooperate in the transcriptional regulation of this gene.
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Figure 3. Lack of IBP Leads to Aberrant
Production of IL-17 and IL-21 In Vitro and
In Vivo
(A) Naive CD4+ T cells derived from 6-week-old
Def6+/+ DO11.10 (white bars) or Def6trap/trap
DO11.10 (black bars) mice were cultured with
Def6+/+ APCs pulsed with 1 mM OVA323-339 pep-
tide for the times indicated. The production of
IL-17, IL-21, and IL-2 in the supernatants was
measured by ELISA. Data showmean ±SD of trip-
licates. Experiment shown is representative of
three independent experiments.
(B) Naive CD4+ T cells derived from 6-week-old
Def6+/+ DO11.10 (white bars) or Def6trap/trap
DO11.10 (black bars) mice were cultured for
3 days as described above, and the mRNA ex-
pression of RORgt (left panel) and IL-22 (right
panel) genes was measured by real-time RT-
PCR. Data show mean ± SD of triplicates. Exper-
iment shown is representative of three indepen-
dent experiments.
(C) Serum concentrations of IL-17 and IL-21 in
Def6+/+ DO11.10 and Def6trap/trap DO11.10 mice.
Sera from Def6+/+ DO11.10 and Def6trap/trap
DO11.10 mice (12–25 weeks old, male and fe-
male, n = 4) were collected and amounts of IL-
17 and IL-21 were analyzed by ELISA. Horizontal
lines denote mean values. *p < 0.05.
(D) Expression of IL-17 and IL-21 in the joints of ar-
thritic Def6trap/trap DO11.10 mice. Joints from
three pairs of Def6+/+ DO11.10 and Def6trap/trap
DO11.10 mice (12–25 weeks old, male and fe-
male) were collected, and IL-17 and IL-21 gene
expression was analyzed by real-time RT-PCR.
White bars represent Def6+/+ DO11.10 mice and
black bars represent Def6trap/trap DO11.10 mice.
Data show mean ± SD of triplicates.
(E) Blimp-1 and CD3 staining of spleens of
Def6trap/trap DO11.10 mice. Anti-Blimp-1 (blue)
and anti-CD3 (red) staining was performed on
spleens from Def6+/+ DO11.10 (left panel) and
Def6trap/trap DO11.10 (right panel) mice. Light mi-
croscopy images (magnification of 4X and 40X)
are shown.Immunity 29, 899–911, December 19, 2008 ª2008 Elsevier Inc. 903
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IBP Inhibits IL-17 and IL-21 Production by Regulating IRF-4Absence of IBP Leads to Enhanced Targeting
of the IL-17 and IL-21 Promoters by IRF-4
We had previously reported that IBP can be found in the cyto-
plasm and can be rapidly recruited to the immunological syn-
apse (Gupta et al., 2003a). IBP, however, also contains putative
NLS motifs (Gupta et al., 2003b), raising the possibility that it
could also translocate to the nucleus. Subcellular-fractionation
experiments indeed demonstrated that IBP could be detected
not only in the cytoplasm but also within the nuclear compart-
ment of primary CD4+ T cells (Figure 5A). Coimmunoprecipitation
experiments confirmed that nuclear IBP and IRF-4 can physically
interact (Figure 5B).
Because we had observed that, in addition to the IL-21 pro-
moter, the IL-17 promoter also contains a potential binding site
for IRF-4, ChIP assays with an IRF-4 Ab were conducted next
to examinewhether the absenceof IBP could lead to deregulated
recruitment of IRF-4-containing complexes to the IL-17 and IL-21
promoters in vivo. When T cells were cultured under unskewed
conditions, the lack of IBP resulted inmarkedly enhanced target-
ing of these regulatory regions by IRF-4-containing complexes
(Figure 5C). To further confirm these findings,weutilized anoligo-
nucleotide corresponding to the IRF-4-binding elementwithin the
IL-21 promoter to perform oligonucleotide precipitation assays
(ONPs) on extracts obtained from wild-type or Def6trap/trap
CD4+ T cells that had either been left unstimulated or stimulated
under neutral conditions (Figure 5D). Consistent with the ChIP
findings, the amounts of IRF-4 that were precipitated from stim-
ulated Def6trap/trap CD4+ T cells were much greater than those
precipitated from stimulated wild-type CD4+ T cells despite sim-
ilar input amounts of IRF-4 (Figure 5D, upper panel). Interestingly,
reblotting with an IBP antibody did not demonstrate any binding
of IBP to this oligonucleotide inwild-type T cells (Figure 5D, lower
panel). Taken together, thesedata support thenotion that nuclear
IBP can regulate the ability of IRF-4 to access the transcriptional
regulatory regions of the IL-17 and IL-21 genes.
IBP Prevents the Ability of IRF-4 to Bind
and Transactivate the IL-21 Promoter
To explore the mechanisms by which IBP controls IRF-4, we first
investigated whether IBP could regulate the translocation of
IRF-4. Subcellular-fractionation experiments (Figure 6A) failed
to demonstrate any effect of the absence of IBP on the cellular
localization of IRF-4, suggesting that the differential ability of
IRF-4 to target the IL-17 and IL-21 promoters was not simply
the result of changes in its subcellular localization.
We next examined the possibility that nuclear IBP may be able
to sequester IRF-4 by determining whether IBP could prevent
IRF-4 from targeting its DNA binding site within the IL-21
A B
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Figure 4. IRF-4 Is a Critical Regulator of Both IL-17
and IL-21 Production
(A) IL-17 production by Irf4+/+ and Irf4/CD4+ T cells. Purified
naive CD4+ T cells were stimulated under either Th0 (white
bars) or Th17 (black bars) cell conditions for 4 days. IL-17
concentrations in culture supernatants were determined by
ELISA. The experiment is representative of four independent
experiments.
(B) Intracellular IL-17and IFN-gproductionby Irf4+/+ and Irf4/
CD4+ T cells. Cells were cultured under Th17 cell conditions as
above and thenstimulatedwithPMAand ionomycin for 5 hr. In-
tracellular IFN-gand IL-17productionwasmeasuredbyFACS.
The experiment is representative of three independent exper-
iments.
(C) IL-21 production by Irf4+/+ and Irf4/ CD4+ T cells cul-
tured under Th17 cell conditions. Purified naive CD4+ T cells
were stimulated under Th17 cell conditions for 4 days and
then restimulated for either 24 hr (white bars) or 48 hr (black
bars). IL-21 concentrations in culture supernatants were de-
termined by ELISA. The experiment is representative of four
independent experiments.
(D) IL-21 production by Irf4+/+ and Irf4/ CD4+ T cells cul-
tured under Th0 and Th2 cell conditions. Purified naive
CD4+ T cells were stimulated under Th0 (white bars) or Th2
(black bars) cell conditions for 7 days and then restimulated
for 48 hr. IL-21 amounts in culture supernatants were deter-
mined by ELISA. The experiment is representative of four in-
dependent experiments.
(E) Effects of IRF-4 on the transactivation of IL-21. Jurkat cells
that express an empty vector or Jurkat cells expressing IRF-4
were transfected with a luciferase reporter construct driven
either by the murine IL-21 promoter (IL-21 LUC) or by a murine
IL-21 promoter containing mutations within the putative IRF-4
binding site (IL-21 MUT LUC) or with a control luciferase re-
porter construct (pGL3) in the presence or absence of PMA
and ionomycin as indicated. Cotransfectionwith a renilla-lucif-
erase construct was performed to normalize the transfection
efficiency of the different samples. Data are representative of
three independent experiments. All graphs show mean ± SD.904 Immunity 29, 899–911, December 19, 2008 ª2008 Elsevier Inc.
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Figure 5. The Absence of IBP Leads to
Enhanced Targeting of the IL-17 and IL-21
Regulatory Regions
(A) IBP can be found within the nuclear compart-
ment. Purified CD4+ T cells were either left
unstimulated or stimulated with anti-CD3 and
anti-CD28 for 48 hr. Nuclear and cytoplasmic ex-
tracts were then prepared and analyzed by immu-
noblotting with an IBP antiserum (upper panel). The
blot was later stripped and reprobed with anti-
lamin B (middle panel) or anti-tubulin (lower panel)
so that the purity of the different fractions could be
assessed.
(B) Nuclear IBP interacts with IRF-4. Purified CD4+
T cells were stimulated with anti-CD3 and anti-
CD28 for 48 hr. Nuclear extracts were then pre-
pared and immunoprecipitated with anti-IRF-4
(‘‘IRF-4 IP’’) or with a control antibody (‘‘Control
Ab IP’’). The immunoprecipitates were then ana-
lyzed by immunoblotting using an IBP antiserum
(upper panel). The blot was later stripped and
reprobed with an IRF-4 antibody (lower panel).
(C) Lack of IBP leads to enhanced targeting of
the IL-17 and IL-21 promoter by IRF-4 in vivo.
CD4+ T cells were purified from either Def6+/+ or
Def6trap/trap mice, cultured under Th0 cell condi-
tions for 7 days, and then either left unstimulated
(‘‘unst’’) or restimulated for 24 hr (‘‘st’’) with
anti-CD3 and anti-CD28. ChIP assays were then
carried out on these cells with either an IRF-4 or
a control antibody, and PCR for the IL-21 and
IL-17 promoters was performed as indicated. The
total input control is shown on the left. Actin was
used as a negative control.
(D) Lack of IBP leads to enhanced binding of IRF-4 to the IRF-4 binding site within the IL-21 promoter. CD4+ T cells were purified from eitherDef6+/+ orDef6trap/trap
mice, cultured as described in (C) and subjected to an oligonucleotide-precipitation assay (ONP) with a biotin-labeled oligonucleotide corresponding to the IRF-4
binding site within the IL-21 promoter. Precipitates were analyzed by immunoblotting with an IRF-4 antibody (top panel). The amounts of IRF-4 in the input
samples are shown on the right (Because of the high amounts of IRF-4 in the input extracts, a shorter exposure time of the IRF-4 input is shown.). The blot
was then stripped and reprobed with an IBP antiserum (lower panel). The amounts of IBP in the input samples are shown on the right.promoter. To facilitate these experiments, we first conducted
a mutational analysis to better define the region of IBP involved
in the interaction with IRF-4 (Figure 6B). This analysis revealed
that a mutant of IBP (IBP 1-385) lacking a large portion of the
carboxy-terminus of IBP (between aa 386 and 631) lost its ability
to interact with IRF-4. Consistent with the finding that the
N-terminal domain can exert an autoinhibitory effect, a mutant
lacking this region (IBPDN) instead exhibited an enhanced
interaction with IRF-4. Oligonucleotide precipitation (ONP) ex-
periments with an oligonucleotide containing the IRF-4-binding
element within the IL-21 promoter were next performed on
extracts of 293T cells transfected with IRF-4 in the presence or
absence of FL IBP, IBPDN, or IBP 1-385 (Figure 6C). IRF-4
was robustly precipitated from 293T cells transfected with
IRF-4 alone but not frommock-transfected 293T cells. The pres-
ence of either FL IBP or IBPDNmarkedly diminished the amount
of precipitated IRF-4. In contrast, strong binding of IRF-4 to this
site could still be detected in 293T cells cotransfected with IBP
1-385. Input amounts of IRF-4 in the different samples were sim-
ilar. IBP can thus directly inhibit the ability of IRF-4 to bind to the
IL-21 promoter.
The effects of IBP on the transactivating activity of IRF-4 were
also examined. Jurkat cells that either lack or contain IRF-4 were
transiently transfected with the IL-21 luciferase reporterconstruct in the presence or absence of FL IBP, IBPDN, or IBP
1-385 (Figure 6D). Cellswere then either left unstimulated or stim-
ulated with PMA and ionomycin. Similar to the results in Figure 4,
presence of IRF-4 augmented the inducibility of this construct
upon PMA and ionomycin stimulation. Consistent with our previ-
ous findings that, in T cells, FL IBP needs to be posttranslationally
modified in order to become activated, coexpression of FL IBP
was unable to affect the transactivating ability of IRF-4, whereas
cotranfection of IBPDN blocked the IRF-4-mediated transactiva-
tion. Importantly, the IBP 1-385 mutant that loses its ability to
physically interact with IRF-4 was unable to markedly affect the
transactivating ability of IRF-4 confirming the functional rele-
vance of the IBP-IRF-4 interaction. To ensure that the inability
of the IBP 1-385 mutant to interfere with the transactivating
activity of IRF-4 was not due to the presence of the N-terminal
autoinhibitory domain, we also generated an IBP mutant lacking
both the autoinhibitory domain and the IRF-4 interacting domain
(DN-385). Cotransfection of (DN-385) with IRF-4 also failed to
block the IRF-4-mediated transactivation of the IL-21 luciferase
reporter construct (Figure S9), confirming that the ability of IBP
to interfere with the ability of IRF-4 to drive the expression of
IL-21 is dependent on its physical interaction with IRF-4.
To finally ascertain whether the ability of IBP to regulate IRF-4
was indeed responsible for the aberrant production of IL-17 andImmunity 29, 899–911, December 19, 2008 ª2008 Elsevier Inc. 905
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Figure 6. IBP Inhibits the DNA Binding and
Transactivating Activity of IRF-4
(A) The absence of IBP does not alter the expres-
sion or localization of IRF-4. CD4+ T cells were
purified from either Def6+/+ or Def6trap/trap mice,
cultured under Th0 cell conditions for 7 days,
and then either left unstimulated (‘‘unst’’) or re-
stimulated for 24 hr (‘‘st’’) with anti-CD3 and
anti-CD28. Nuclear and cytoplasmic extracts
were then prepared and analyzed by immunoblot-
ting with an IRF-4 antibody (upper panel). The blot
was later stripped and reprobed with a lamin B
(middle panel) or a tubulin (lower panel) antibody
so that the purity of the different fractions could
be assessed.
(B) Mapping of the IBP domain responsible for the
interaction with IRF-4. 293T cells were cotrans-
fected with an IRF-4 expression construct to-
gether with either HA-tagged full-length IBP or
the panel of HA-tagged IBP mutants described
in the diagram. Extracts were immunoprecipitated
with a HA antibody and analyzed by immunoblot-
ting with an IRF-4 antibody (top panel). The blot
was later stripped and reprobed with a HA
antibody (bottom panel).
(C) IBP can block the binding of IRF-4 to an oligo-
nucleotide containing the IRF-4 binding site within
the IL-21 promoter. An oligonucleotide-precipita-
tion assay (ONP) was performed on 293T cells
that were either mock transfected or transfected
with IRF-4 in the presence or absence of HA-
tagged FL IBP, HA-tagged IBPDN, or HA-tagged
IBP 1-385. Precipitates were analyzed by immu-
noblotting with an IRF-4 antibody (left panel).
The amounts of IRF-4 in the input samples are
also shown (Because of the high amounts of
IRF-4 in the extracts, a shorter exposure time of
the IRF-4 input is shown.). A nonspecific band de-
tected in the ONP from mock-transfected 293T
cells is indicated as ‘‘ns.’’ The blot was later strip-
ped and reprobed with a HA antibody so that the
amounts of the different IBP constructs in the in-
put samples could be assessed (right panel).
(D) IBP can inhibit the transactivating activity of
IRF-4. Jurkat cells that express an empty vector
or Jurkat cells expressing IRF-4 were transfected
with a luciferase reporter construct driven by the
murine IL-21 promoter (IL-21 LUC) together with
an empty vector, HA-tagged FL IBP, HA-tagged IBPDN, or HA-tagged IBP 1-385 as indicated. Cells were either left unstimulated or stimulated with PMA and
ionomycin as indicated. Transfections with a control luciferase reporter construct (pGL3) in the presence or absence of PMA and ionomycin were also carried
out. We performed cotransfection with a renilla-luciferase construct to normalize the transfection efficiency of the different samples. Data showmean ± SD. Data
are representative of three independent experiments.IL-21 observed in Def6trap/trap mice, we generated mice deficient
in both IBP and IRF-4. As expected from previous studies dem-
onstrating that neither a deficiency of IRF-4 nor a lack of IBP
lead to obvious developmental defects (Fanzo et al., 2006; Mit-
tru¨cker et al., 1997), Def6trap/trapIrf4/ mice were viable, were
fertile, anddid not exhibit any significant defects in thematuration
of the immunesystem (TableS1). To assesswhether lack of IRF-4
could alter the deregulated production of IL-17 observed in the
absence of IBP, we cultured naive CD4+ T cells under unskewed
conditions and assessed IL-17 production in the supernatants by
ELISA. The lack of IRF-4 completely abolished the increased abil-
ity ofDef6trap/trap T cells to synthesize IL-17 (Figure 7A). In linewith
prior observations that IRF-4 controls the expression of RORgt,906 Immunity 29, 899–911, December 19, 2008 ª2008 Elsevier Inc.the aberrant RORgt expression detected in the absence of
IBP was also dependent on the presence of IRF-4 (Figure 7B).
Consistent with a critical role for IRF-4 not only in the control of
IL-17 but also in the regulation of IL-21, absence of IRF-4 also
prevented the enhanced ability of Def6trap/trap T cells to produce
IL-21 when the T cells were cultured under either unskewed
conditions (Figure S10) or Th2 cell conditions (Figure 7C). These
defects were not due to abnormalities in proliferation because
CD4+ T cells from mice of all four genotypes exhibited similar
CFSE profiles (Figure 7D). Furthermore, differences in IL-17 pro-
duction under these conditions did not simply correlate with
differential ability of the four T cell populations to produce TGF-b
or IL-6 (Figure S10). Interestingly, in contrast to the findings with
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affected the induction of ICOS upon T cell stimulation in vitro
(Figure S10). These results thus indicate that the enhanced ability
of IBP-deficient T cells to aberrantly produce IL-17 and IL-21 is
critically dependent on the presence of IRF-4.
DISCUSSION
Although T cells play a key role in the pathogenesis of many
autoimmune diseases such as RA and SLE, the molecular ma-
chinery preventing the emergence of autoreactive T cells has
not been fully elucidated. Our studies suggest that deregulation
of IBP-controlled pathways represents an important pathogenic
mechanism leading to the spontaneous development of autoim-
munity. The ability of IBP to play a critical role in this process is
probably due to its capacity to control the responsiveness of
T cells to pMHC complexes and to ensure that the production
of IL-17 and IL-21 does not occur in the absence of the proin-
flammatory conditions known to drive Th17 cell differentiation.
One of the crucial aspects underlying the spontaneous devel-
opment of autoimmunity in IBP-deficient mice is the inability of
Def6trap/trap T cells to accurately sense the strength of TCR en-
gagement.Def6trap/trap DO11.10 T cells exhibit a highly abnormal
pattern of responsiveness. In line with our previous findings
that polyclonal IBP-deficient T cells exposed to strong stimula-
tory conditions proliferate to a lesser extent than wild-type
T cells (Fanzo et al., 2006), Def6trap/trap DO11.10 T cells exhibit
defective proliferative responses upon exposure to high doses
of OVA323-339 peptide.Def6
trap/trap DO11.10 T cells, however, ex-
hibit enhanced proliferative responses to low levels of stimula-
tion, an effect also observed with polyclonal IBP-deficient
T cells (unpublished data). The hyperresponsiveness of the
Def6trap/trap DO11.10 CD4+ T cells to low levels of stimulation
was corroborated by their spontaneous activation in vivo in the
absence of any exposure to ovalbumin and by their enhanced
expression of CD5. Increased CD5 expression was also seen
on CD4 SP cells from newborn Def6trap/trap DO11.10 mice, sug-
gesting that this phenotype was due to intrinsic changes in the
recognition of the DO11.10 TCR for its ligands rather than to ex-
posure to a pathogenic environment. Preliminary studies from
Def6trap/trapRag1/ DO11.10 mice that we have recently gener-
ated reveal that TCR transgenic T cells from thesemice still retain
the observed abnormalities, suggesting that the arthritis and vas-
culitis occurring inDef6trap/trap DO11.10mice are due to the inap-
propriate recognition of crossreactive epitopes by the DO11.10
TCR and not to the expression of a second TCR by these cells.
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Figure 7. The Deregulated IL-17 and IL-21 Production Observed in the Absence of IBP Is Dependent on IRF-4
(A) IL-17 production by wild-type, Def6trap/trap, Irf4/, and Irf4/Def6trap/trap CD4+ T cells. Purified naive CD4+ T cells were stimulated under Th0 cell conditions
for 4 days. IL-17 concentrations in culture supernatants were determined by ELISA.
(B) RORgt expression by wild-type, Def6trap/trap, Irf4/, and Irf4/Def6trap/trap CD4+ T cells. Purified naive CD4+ T cells were stimulated as above and RORgt
gene expression was determined by real-time RT-PCR.
(C) IL-21 production by wild-type, Def6trap/trap, Irf4/, and Irf4/Def6trap/trap CD4+ T cells. Purified naive CD4+ T cells were stimulated under Th2 cell conditions
for 7 days and then restimulated for 48 hr. IL-21 concentrations in culture supernatants were determined by ELISA. All graphs show mean ± SD.
(D) CFSE profiles of wild-type, Def6trap/trap, Irf4/, and Irf4/Def6trap/trap CD4+ T cells that were either left unstimulated (red) or stimulated under Th0 cell
conditions for 2 days (blue) or for 4 days (green). Experiments shown are representative of three independent experiments.Immunity 29, 899–911, December 19, 2008 ª2008 Elsevier Inc. 907
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capacity of T cells to acquire a potentially pathogenic effector
program. Indeed, one of the crucial abnormalities observed in
the absence of IBPwas increased production of IL-17, a cytokine
with known proinflammatory effects relevant to the pathophysi-
ology of RA (Koenders et al., 2006; Stamp et al., 2004). The
deregulated production of IL-17 by IBP-deficient T cells was
critically dependent on IRF-4, a transcription factor shown to
be necessary for Th17 cell differentiation (Brustle et al., 2007).
Interestingly, IRF-4 is a key cellular target of the HTLV-I Tax on-
coprotein (Mamane et al., 2002), and it is intriguing to speculate
that deregulation of IRF-4may also play a role in the autoimmune
arthritis associated with Tax overexpression (Habu et al., 1999).
Consistent with the finding that IRF-4 can regulate the expres-
sion of RORgt (Brustle et al., 2007), the enhanced production
of IL-17 by IBP-deficient T cells was accompanied by increased
expression of RORgt, an effect that required the presence of
IRF-4. Reconstitution of RORgt expression in IRF-4-deficient
T cells only partially restores the deficient IL-17 production ex-
hibited by these cells (Brustle et al., 2007). Thus, our finding
that IRF-4 can also target the regulatory regions of the IL-17
gene indicates that the role of IRF-4 in Th17 cell differentiation
is multifaceted and includes both direct effects on the transcrip-
tion of the gene that encodes IL-17 and indirect effects on the
expression of other IL-17 transactivators.
The acquisition of a Th17 cell phenotype normally requires the
sequential exposure of Th17 cells to key cytokines (Bettelli et al.,
2007a; Ivanov et al., 2007). Presence of IL-6 is crucial for the
initiation of this process and leads to the induction of IL-21 pro-
duction, which, in turn, acts in an autocrine manner and further
amplifies commitment of Th cells toward the Th17 cell lineage.
Our studies demonstrate that IBP-deficient T cells can produce
IL-21 even during the initial stimulation by antigen and in the
absence of any Th17 cell-skewing conditions. This abnormality
may have profound pathophysiologic consequences because
aberrant synthesis of IL-21 may not only reinforce the abnormal
IL-17 production exhibited by these cells but also enable these
CD4+ T cells to inappropriately promote the terminal differentia-
tion of B cells at extrafollicular sites and, thus, provide help to
autoreactive B cells (William et al., 2002). Consistent with this no-
tion, the lack of IBP leads to the aberrant localization of plasma
cells within peripheral lymphoid organs and to the presence of
autoantibodies. By controlling IL-21 production, IBP may thus
play a critical role in ensuring that T cell help to B cells is provided
only to appropriately selected B cell populations (Vinuesa et al.,
2005). Unlike what we observed with IL-17 and IL-21, IBP defi-
ciency did not affect the production of IL-22 in agreement with
studies showing that the regulation of IL-22 differs from that of
IL-17 and that IL-22 primarily functions as a downstream target
of IL-23 (Ouyang et al., 2008).
Similarly to IL-17, the ability of IBP to control IL-21 production
is dependent on its interaction with IRF-4. Consistent with the
finding that SWAP-70 contains three nuclear localization signals
and can be detected in the nucleus of activated B cells (Masat
et al., 2000), IBP could be detected in T cells’ nuclear compart-
ment in which it ‘‘sequestered’’ IRF-4, preventing it from binding
and transactivating the IL-21 promoter. The interaction of IBP
and IRF-4 requires its carboxy-terminus, which is also important
for the ability of IBP to activate Rho GTPases (Gupta et al.,908 Immunity 29, 899–911, December 19, 2008 ª2008 Elsevier Inc.2003a). Experiments are now in progress to determine whether
the two functions of IBP map to distinct subdomains within its
carboxy-terminal region. Unlike other master regulators of Th
cell differentiation like GATA3 and RORgt, the expression of
IRF-4 is upregulated by TCR stimulation and is not restricted to
a specific Th effector cell lineage (Matsuyama et al., 1995;
Rengarajan et al., 2002). The presence of mechanisms that
restrain the access of IRF-4 to selected regulatory regions may
thus be particularly important to ensure that its activity can be
controlled in a Th cell lineage-specific manner.
In contrast to Def6trap/trap DO11.10 mice, young Def6trap/trap
Balb/c mice do not develop obvious signs of arthritis, although
evidence of a systemic autoimmune disease can be observed
in these mice upon aging (unpublished data). T cells derived
fromDef6trap/trap Balb/cmice, however, do exhibit abnormal pro-
duction of IL-17 and IL-21 upon in vitro stimulation (unpublished
data). These findings suggest that the pathogenic effector func-
tion observed in the absence of IBP becomes unmasked in the
setting of a restricted TCR repertoire (i.e., in the DO11.10 TCR
transgenic background) and/or of declining T cell numbers (i.e.,
upon aging). Because the lack of IBP leads to an exaggerated
ability to undergo homeostatic proliferation (unpublished data),
the pathogenicity of the IBP-deficient T cells may become
evident only after these T cells receive a signal to expand in order
to replenish themature T cell pool. Interactions with other cellular
constituents may also be required for IBP-deficient T cells to fully
acquire their pathogenic potential. Indeed, IBP-deficient T cells
exhibit markedly elevated expression of ICOS in vivo but not
in vitro, suggesting that the deregulated ICOS expression
observed in these mice is under complex regulation. We thus
envision a scenario whereby the deregulated production of
IL-17 and IL-21 by IBP-deficient T cells, via the effects of these
cytokines on other cellular compartments, leads to additional
aberrations within T cells eventually resulting in the development
of autoimmunity.
Absence of IBP can thus result in the development of either
a lupus-like syndrome or RA-like joint disease. The finding that
IBP deficiency can lead to these distinct autoimmune manifesta-
tions is consistent with the fact that familial aggregation of RA
and SLE has been reported (Alarcon-Segovia et al., 2005;
Criswell et al., 2005). Deregulation of IL-17 and IL-21 production
has also been detected in murine models of RA and SLE and in
patients affected by these diseases (Afzali et al., 2007; Herber
et al., 2007; McInnes and Schett, 2007; Sawalha et al., 2007).
Blockade of the IL-21-IL-21R pathway has recently been re-
ported to be efficacious in ameliorating disease inmurinemodels
of both SLE and RA (Herber et al., 2007; Young et al., 2007). The
capacity of IBP to control both TCR responsiveness and the
production of IL-17 and IL-21 thus suggest that deregulation of
IBP-mediated pathways could function as a common patho-
genic mechanism involved in the development of these two
distinct autoimmune disorders.
EXPERIMENTAL PROCEDURES
Mice
IBP-deficient mice were generated by Lexicon Pharmaceuticals (Omnibank)
with a gene-trapping strategy and hence have been termed Def6trap/trap mice
(Fanzo et al., 2006). The original mice (on a mixed 129XC57BL/6 background)
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We then crossed Def6trap/trap mice on a Balb/c background to DO11.10 TCR
transgenic mice (Jackson Laboratory) to generate Def6trap/trapDO11.10 mice;
Def6trap/trap mice on a C57BL/6 background were crossed to HY-TCR trans-
genic mice (Taconic) to generate Def6trap/trapHY mice. Irf4/ mice on a
C57BL6 background were obtained from T. Mak at Departments of Immunol-
ogy and Medical Biophysics, University of Toronto and the Amgen Institute
(Mittru¨cker et al., 1997). To generate Def6trap/trapIrf4/ mice, we crossed
Irf4/ mice with Def6trap/trap mice that had been backcrossed onto the
C57BL/6 background. Syngeneic SCID and nude mice were obtained from
Jackson Laboratory. All mice used in the experiment were kept under specific
pathogen-free conditions. The experimental protocols were approved by the
Institutional Animal Care and Use Committee of Columbia University.
Flow Cytometry
Single-cell suspensions from thymus, spleen, and lymph nodes were isolated,
stained with fluorochrome-conjugated KJ1-26 (Caltag laboratories), CD33,
CD4, CD5, CD8, B220, CD25, CD44, CD62L, CD69, (PharMingen), T3.70,
and ICOS antibodies (eBiosciences), and analyzed by FACS. Data were
analyzed with FlowJo (Treestar) software.
Clinical Assessment of Arthritis
Joint swelling was monitored by inspection and scored as follows: 0, no evi-
dence of erythema and swelling; 1, erythema and mild swelling confined to
the wrist or ankle; 2, erythema and mild swelling extending from the wrist or
ankle to the mid-paw; 3, erythema and moderate swelling extending from
the wrist or ankle to themid-paw; and 4, erythema and severe swelling encom-
passing the wrist or ankle, paws, and digits. Score for all four paws were
totaled for each mouse (Brand et al., 2004).
Histopathology and Immunohistochemical Staining
Tissue specimens were fixed in 10% neutral buffered formalin and embedded
in paraffin. Tissue sections were stained with hematoxylin and eosin (H & E)
and analyzed by light microscopy. Joints were fixed in 10% phosphate-
buffered formalin, decalcified in 10% EDTA-4Na, and embedded in paraffin.
Immunostaining of spleen sections with antibodies against CD3, Blimp-1,
and Syndecan-1 was performed as previously described (Angelin-Duclos
et al., 2000; Fanzo et al., 2006).
Serum Autoantibodies
Serum levels of RF and of antibodies against collagen II, CCP, and double-
stranded DNA (dsDNA) were determined by ELISA (Alpha Diagnostics for
RF, CII, and dsDNA Abs and Axis-Shield Diagnostics for CCP Abs) as de-
scribed (Kuhn et al., 2006; Sakaguchi et al., 2003). Data were analyzed with
Student’s t test.
In Vivo Thymocyte Deletion
We injected 6-week-old mice with 250 mg of anti-CD3 antibody i.p. as previ-
ously described (Sakaguchi et al., 2003). Seventy-two hours later, mice were
sacrificed and the thymus was collected. Total thymocytes were counted,
stained for CD4 and CD8, and analyzed by FACS.
Proliferation Studies and Cytokine Production
Naive CD4+ T cells were purified as previously described (Lin et al., 2004) or, in
selected experiments, by sorting CD44loCD62LhiCD25CD4+ T cells. For pro-
liferation assays, cells were cultured at 1 3 105 per well in 96-well plates
together with 4 3 105 syngeneic Def6+/+ APCs loaded with increasing doses
(0, 0.1, 1, and 10 mM) of OVA323-339 peptide for 48 hr as described (Song
et al., 2005) and then pulsed with BrdU for 18 hr. Incorporated BrdU was mea-
sured by BrdU ELISA (Roche-Applied-Science). For cytokine analysis, 13 106
cells/ml were stimulated with 4 3 106 APC loaded with OVA323-339 peptide at
1 mM concentration in 24-well plates. Th0 and Th2 cell differentiation was con-
ducted as previously described (Fanzo et al., 2006). For Th17 cell differentia-
tion, naive purified CD4+ T cells were activated by plate-bound anti-CD33
and soluble anti-CD28 in the presence of anti-IFN-g (10 mg/ml, BD Biosci-
ences), anti-IL4 (10 mg/ml, BD Biosciences), IL6 (20 ng/ml, Peprotech), and
TGF-b (5 ng/ml, Peprotech) as previously described (Ivanov et al., 2006).Supernatants were analyzed for IL-21 (R&D Systems), IL-17, IFN-g (eBio-
science), TGF-b (eBioscience), and IL-2 (eBioscience) production by ELISA.
Transient-Transfection Assays
Transient transfection assays were performed as previously described (Hu
et al., 2002). In brief, 10 3 106 control or IRF4-expressing Jurkat cells were
transfected with 5 mg of a murine IL-21 promoter-luciferase reporter plasmid
(Mehta et al., 2005) by electroporation at 260V and 960 mF with a BTX electro-
porator. A total of 100–200 ngof the pRL-TK reporter plasmid expressing renilla
luciferase under the control of the thymidine kinase promoter was added to
each transfection as a transfection-efficiency control. After transfection, the
cells were allowed to recover for 16 hr at 37C, 6% CO2. The cells were then
collected and resuspended in 3 ml of media and equally split into two 1.5 ml
aliquots. The aliquots were then cultured in the presence or absence of PMA
(50 ng/ml) and ionomycin (1 mM) for 4 hr. The transfected cells were then har-
vested, lysed, and assayed for luciferase activities with the Dual Luciferase As-
say System (Promega) according to themanufacturer’s instructions. The firefly
luciferase activity was normalized on the basis of renilla luciferase activity.
Cell Extracts and Protein Assays
Nuclear and cytoplasmic extracts were preparedwith theNE-PERNuclear and
Cytoplasmicextraction reagent kit aspreviouslydescribed (Soet al., 2006). The
purity of the nuclear and cytoplasmic fractions was verified by probing with
antibodies against Lamin B (sc-6217, Santa Cruz Biotechnology) and Tubulin
(clone D66, Sigma-Aldrich). Cell lysates were immunoprecipitated with an
IBP or IRF-4 antibody as previously described (Gupta et al., 2003a). The immu-
noprecipitates were resolved by 8%SDS-PAGE, transferred to a nitrocellulose
membrane, and immunoblotted with an IRF-4 or an IBP antibody. The protein
bands were visualized by ECL (Amersham). Chromatin immunoprecipitation
(ChIP) assays were performed as previously described (Sciammas et al.,
2006). In brief, CD4+ T cells were purified from Def6+/+ mice and Def6trap/trap
mice and either left unstimulated or stimulated for 24 hr under unskewed
conditions. After harvesting, the cells were crosslinked with formaldehyde,
and chromatin extracts were prepared by standard methods and subjected
to immunoprecipitation with an IRF-4 specific antibody or a control antibody.
After crosslinking was reversed and proteins digested, the DNA was purified
from the immunoprecipitates as well as from input extracts and then analyzed
by PCR with primers specific for the murine IL-21 promoter (50-CCCTTGTG
AATGCTGAAAACTG-30 and 50-GGCCTTGGTCTGGTTCTCACT-30), the IL-17
promoter (50-GCGGTACTCAGTTAAATAGAACGT-30 and50-ATTAGTGCAGGA
CTCACCACAGA-30), or b-actin (50-GCTCCTCCTGAGCGCAAGT-30 and 50-TC
GTCATACTCCTGCTTGCTGAT-30). Oligonucleotide precipitation (ONP) as-
says were conducted as previously described (Azam et al., 1997). In brief,
nuclear extracts were precleared with streptavidin-agarose beads and then
incubated with biotinylated double-stranded oligonucleotide corresponding
to the trimerized IRF-4 binding site within the IL-21 promoter (50-CCTTGG
TGAATGCTGAAAACTGGAATTCACCCAT-30). Proteins bound to the biotin-
labeled DNA were collected by streptavidin-agarose beads, separated by
8% SDS-PAGE, and analyzed by western blotting.
Real-Time RT-PCR
Total RNA was isolated from cells or organs with the RNeasy Mini Kit (QIAGEN
GmbH). cDNAs were prepared and analyzed for the expression of the gene of
interest by real-time PCR with a Sybr-Green PCR master mix kit (Applied
Biosystems). The primers for IL-17, IL-21, IL-22, and RORgt genes have
been previously described (Chung et al., 2006; Lubberts et al., 2005; Wurster
et al., 2002; Xi et al., 2006). The expression of each gene was normalized to the
expression of b-actin.
Adoptive Transfers
For splenocyte transfers, cells suspensions were obtained from either arthritic
Def6trap/trapDO11.10 mice or age- and sex- matched Def6+/+DO11.10 mice,
and 23 107 cells were injected i.v. into syngeneic SCID mice. For T cell trans-
fers, lymphocytes were pooled from peripheral lymph nodes and spleen, and
total CD4+ T cells were positively selected by MACS magnetic beads sorting
(Miltenyl Biotec) and stained with the KJ1-26 Ab (Caltag Laboratories). KJ1-
26hi and KJ1-26lo cells were sorted by FACSDiva (BD Biosciences). The sortedImmunity 29, 899–911, December 19, 2008 ª2008 Elsevier Inc. 909
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IBP Inhibits IL-17 and IL-21 Production by Regulating IRF-4cells were thenwashed and 23 106 cells were injected i.v. into syngeneic nude
mice.
Regulatory T Cell-Suppression Assays
CD4+ T cells (5 3 104) from Def6+/+DO11.10 mice were cultured in 96-well
plates with T cell-depletedMitomycin C (Sigma)-treated APCs (23 105) pulsed
with OVA323-339 (1 mM) in the presence or absence of increasing numbers
of FACS-sorted CD4+CD25+ regulatory T cells from Def6+/+DO11.10 or
Def6trap/trap DO11.10 mice for 72 hr as previously described (Thornton and
Shevach, 2000). For proliferation assays, cultures were pulsed with [3H]-thymi-
dine (PerkinElmer) for the last 12 hr of culture.
SUPPLEMENTAL DATA
Supplemental Data include ten figures and one table and can be found
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